CD274 and non-small cell lung carcinoma: Interestingly, one patient, pat.#15 which demonstrated 100% PD‐L1 positivity in NSCLC tumor tissue by IHC (Table 1) and whose FNA sample showed the highest level of PD‐L1 in PEA analyses was treated with pembrolizumab during several courses and responded well.